Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
3.100
+0.010 (0.32%)
Jan 17, 2025, 4:00 PM EST - Market closed
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for AQST stock have an average target of 10.38, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 234.84% from the current stock price of 3.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 20, 2024.
Analyst Ratings
The average analyst rating for AQST stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +222.58% | Dec 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $17 | Buy | Initiates | $17 | +448.39% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +222.58% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +222.58% | Nov 6, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +319.35% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
59.91M
from 50.58M
Increased by 18.44%
Revenue Next Year
54.01M
from 59.91M
Decreased by -9.85%
EPS This Year
-0.47
from -0.13
EPS Next Year
-0.61
from -0.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 64.4M | 65.1M | 92.8M | |||
| Avg | 59.9M | 54.0M | 73.3M | |||
| Low | 56.0M | 41.5M | 45.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 27.2% | 8.7% | 71.9% | |||
| Avg | 18.4% | -9.8% | 35.7% | |||
| Low | 10.6% | -30.8% | -16.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.47 | -0.50 | -0.27 | |||
| Avg | -0.47 | -0.61 | -0.44 | |||
| Low | -0.46 | -0.76 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.